The FDA and NIH have both issued calls for greater diversity in clinical trial enrollment. The reason is simple: medical research that does not represent the full range of patients it intends to help produces results of limited value.
The Historical Gap
For decades, clinical trials enrolled predominantly white male participants. Women were often excluded over concerns about hormone variability affecting results. People of color were underrepresented due to historical distrust, logistical barriers, and lack of targeted outreach.
Real-World Consequences
The consequences of this gap have been measurable:
- BiDil, a heart failure medication, was approved specifically for Black patients after trials showed stronger effects in that population, a result that would have been missed in a homogeneous trial.
- Many drug dosing guidelines are based on data from men, leading to higher rates of adverse drug reactions in women.
- Skin conditions are systematically harder to diagnose on darker skin tones, partly because training images and research images have historically featured only light skin.
Progress Being Made
The FDA Modernization Act and updated NIH inclusion policies now require researchers to make active efforts to enroll diverse populations. Many sponsors offer additional support, including transportation, multilingual coordinators, and community outreach, to increase participation.
NuLine’s Commitment
NuLine Clinical Trial Center is located in one of the most diverse communities in the country. Our team speaks multiple languages and is deeply committed to inclusive research. We welcome participants of all backgrounds. Contact us to learn more.